Oxford Biomedica Solutions
Christopher Park is a seasoned quality assurance professional with extensive experience in the biopharmaceutical industry, specializing in gene therapy. Currently serving as a QA Manager at Oxford Biomedica since January 2023, Christopher previously held roles such as QA/QC Lead Specialist at 2seventy bio and QA Ops Lead Specialist at bluebird bio. Notable accomplishments include leading successful continuous improvement projects at Sanofi Genzyme, resulting in significant reductions in document backlogs and optimization of QA processes. Christopher has a strong educational background, holding a Master's Degree in Engineering/Industrial Management from Tufts, a Master's in Regulatory Affairs from Northeastern University, and a B.A. in Biochemistry and Molecular Biology from Connecticut College.
Oxford Biomedica Solutions
Oxford Biomedica Solutions, LLC is the high-performing, full scope Adeno-Associated Virus (AAV) vector Manufacturing and Innovation joint venture of Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), and Homology Medicines, Inc. (Nasdaq: FIXX) (“Homology”). We offer global pharmaceutical and biotechnology clients innovative manufacturing expertise in AAV and lentiviral-based cell and gene therapies. Oxford Biomedica Solutions LLC provides access to Homology’s innovative and proven end-to-end AAV manufacturing capabilities, and customers also benefit from technical synergies brought in by the Group’s know-how in lentiviral vector manufacturing. This collaborative and complementary vector-based approach has the potential to accelerate our collective mission to improve patients’ lives worldwide.